VK2735
Dual GLP-1 and GIP receptor agonist from Viking Therapeutics. Weekly injection reached -14.7% body weight in just 13 weeks in phase 2.
Calorize — peptide protocol & nutrition tracker
This substance is still in clinical trials and is not approved for use as a medicine in any country. The figures below come from published trial protocols; they describe what was studied, not what you should take.
Every figure on this page is a dose reported in published sources. It is reference information, not a recommendation and not a protocol to follow. Any decision about injecting is one to make with a doctor.
Medical disclaimerWhat is VK2735?
VK2735 is a dual GLP-1 and GIP receptor agonist from Viking Therapeutics — the same mechanism as tirzepatide. It stands out for speed: the 13-week VENTURE study reached up to 14.7% weight reduction.
What follows is dosing arithmetic and numeric protocols drawn from published sources and clinical trials. It describes what those sources report; it is not medical advice and not instructions for use. This part of the page is meant for people aged 18 and over.
The confirmation is kept in this browser, and on the account for signed-in users. The peptide description and its regulatory status are available without it.
What follows is dosing arithmetic and numeric protocols drawn from published sources and clinical trials. It describes what those sources report; it is not medical advice and not instructions for use. This part of the page is meant for people aged 18 and over.
The confirmation is kept in this browser, and on the account for signed-in users. The peptide description and its regulatory status are available without it.
Rapid weight loss burns muscle along with fat — that is what sits behind Ozempic face. Enough protein is what separates the two.
Check Protein Norm